Press Releases Eisai Co., Ltd.

Stocks

4523

JP3160400002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 10:40:58 15/06/2026 am IST			5-day change	1st Jan Change
3,828.00 ^JPY	+1.27%		+0.58%	-17.85%

07:08am	UK, Japan Enter Into GBP 18 Billion Deal to Boost Clean Energy, Jobs, Next-Generation Tech	MT
11/06	Beren Therapeutics P.B.C. announced that it has received $245 million in funding from Eisai Co., Ltd., The Founders Fund, LLC, Wellington Partners Advisory AG, Narya Capital, JIC Venture Growth Investments Co., Ltd. and other investors	CI

Press Releases

21/05	Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026	AQ
08/05	Eisai : Voluntary Recall of Distributed “Halaven®” in the Middle East and Southern Africa	PU
21/04	Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)	AQ
27/03	Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy	AQ
23/03	Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026	AQ
19/03	Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)	AQ
17/03	Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation	AQ
12/03	Exploring Sleep with Pokemon! Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration	AQ
11/03	Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting	AQ
02/03	WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)	AQ
16/02	Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy	AQ
10/02	Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China	AQ
26/01	FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review	AQ
21/01	Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time	AQ
13/01	Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan	AQ
06/01	Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China	AQ
16/12	Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year	AQ
16/12	"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List	AQ
08/12	Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025	AQ
08/12	New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF	AQ
04/12	Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025	AQ
01/12	Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan	AQ
26/11	Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status	AQ
17/11	"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom	AQ
14/11	MHRA approves Leqembi IV maintenance as additional Alzheimer's option	AQ